Azitra Inc
Research Azitra Inc (AZTR) on Bullrun: market cap USD 2.56M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAZTR
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.56M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 3.93M
- Free cash flow-USD 2.51M
Valuation Snapshot
latest market cap is USD 2.56M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 10.96M | -USD 11.25M | n/a | -2.25 | USD 2.07M | USD 422.08K | USD 3.80M |
| FY2024 | USD 7.50K | -USD 8.97M | -USD 10.19M | n/a | -15.7 | USD 4.55M | USD 555.51K | USD 5.70M |
| FY2023 | USD 686.00K | -USD 11.28M | -USD 7.39M | n/a | -54.98 | USD 1.80M | USD 885.95K | USD 2.91M |
| FY2022 | USD 284.00K | -USD 10.68M | -USD 8.38M | n/a | -12.74 | USD 3.49M | n/a | -USD 36.26M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.56M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.79M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.25M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 11.13M | n/a | n/a | n/a |
About Azitra Inc
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Azitra Inc's market cap?
Azitra Inc's market capitalization is USD 2.56M.
What does Azitra Inc do?
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S.